Key result
Targeting histone lactylation offers a potential epigenetic therapy for myocardial ischemia/reperfusion injury.
Why the study?
Myocardial ischemia/reperfusion injury contributes to damage after myocardial infarction revascularization, prompting review of histone lysine lactylation as a metabolic epigenetic regulator and potential therapeutic target.
Elucidating the dynamic patterns of histone lysine lactylation and its involvement in biological processes may create new paradigms and potential therapeutic targets for the prevention and treatment of myocardial ischemia/reperfusion injury.
One important pathogenic process that contributes to subsequent damage after myocardial infarction (MI) revascularization is myocardial ischemia/reperfusion injury (MI/RI). Its underlying mechanisms are controlled by traditional post-translational modifications (PTMs) like acetylation, methylation, phosphorylation, and ubiquitination, and involve several cell death pathways, such as autophagy, apoptosis, pyroptosis, and ferroptosis. Histone lysine lactylation (Kla), a novel metabolically related epigenetic regulation mechanism, has attracted a lot of attention in recent years. This review systematically clarifies the crucial role of lactate in cardiac energy metabolism and its influence on Kla modification, exploring Kla's dual regulatory function in MI/RI. It demonstrates a significant interaction between Kla and changes like acetylation, phosphorylation, N6-methyladenosine (m6A) methylation, and ubiquitination, thereby establishing putative connections that regulate cell death in MI/RI. Targeting lactate-related molecules such as lactate dehydrogenase A (LDHA), monocarboxylate transporters (MCTs), and histone deacetylases (HDACs) shows therapeutic potential. Therefore, targeted intervention molecules applicable at different stages of MI/RI are explored. Ultimately, elucidating the dynamic patterns of Kla and its crucial involvement in various biological processes will create new paradigms and potential therapeutic targets for the prevention and treatment of MI/RI.
No takes yet. Share an insight, caveat, or question.
Yang et al. (2026) conducted a review in Myocardial ischemia/reperfusion injury (MI/RI). Targeting lactate-related molecules (LDHA, MCTs, HDACs) was evaluated. Targeting lactate-related molecules and histone lysine lactylation presents a novel epigenetic regulatory mechanism and potential therapeutic strategy for myocardial ischemia/reperfusion injury.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: